Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 14/20 | 0.38 |
| ▸ | PPARA | Q07869 | 13/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | UTRN | P46939 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064590 | 0.90 | PPARG (0.43) | PPARGPPARAPPARD | |
| SCHEMBL4057732 | 0.88 | PPARG (0.43) | SLC22A12PPARGPPARAPPARDUTRN | |
| SCHEMBL4057020 | 0.87 | PPARG (0.40) | SLC22A12PPARGPPARAPPARDUTRN | |
| SCHEMBL4057869 | 0.86 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL4061500 | 0.84 | SLC22A12 (0.44) | SLC22A12PPARGPPARAPPARD | |
| SCHEMBL4067544 | 0.83 | PPARA (0.47) | SLC22A12PPARGPPARAPPARD | |
| SCHEMBL4062726 | 0.82 | PPARG (0.46) | SLC22A12PPARGPPARAPPARDVDR | |
| SCHEMBL4057676 | 0.82 | PPARA (0.43) | PPARGPPARAPPARD | |
| SCHEMBL4054612 | 0.81 | SLC22A12 (0.44) | SLC22A12PPARGPPARAPPARD | |
| SCHEMBL4055922 | 0.80 | PPARG (0.43) | SLC22A12PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666472-B1 | PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO (JP) | 2012-08-01 | — | — | EP | claimed |
| US-7560475-B2 | Phenylacetic acid derivative, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-14 | — | — | US | claimed |
| US-20070105868-A1 | Phenylacetic acid derivative, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | claimed |
| EP-1666472-A1 | PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | claimed |
| EP-1666472-B1 | PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7560475-B2 | Phenylacetic acid derivative, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070105868-A1 | Phenylacetic acid derivative, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1666472-A1 | PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105868-A1 | Phenylacetic acid derivative, process for producing the same, and use | PPARA, PPARD, PPARG | SLC22A12 1333/4885PPARG 3/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.